Company intelligence / Profile preview

Bondars

St. Louis, Missouri, United Statesbondars.com ↗

Ownership: Private
Development stage: Commercial

Overview

BBI-001, the lead candidate, has demonstrated efficacy in preclinical animal models by binding dietary iron and inhibiting its absorption. It aims to provide an alternative to phlebotomy for hereditary hemochromatosis patients. Human clinical proof-of-concept studies are planned or underway.

Therapeutic areas: Metabolic DisordersHematology
Modalities: Polymer-based therapySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Bondars.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bondars.

Explore the full profile